TTR and kidney disorder: The inhibition of lncRNAs in vivo is technically no more challenging than the inhibition of messenger RNAs; therefore, with an increasing number of antisense oligonucleotide therapies coming into clinical use at the moment (e.g., RNAi for TTR-amyloidosis or modulation of splicing for spinal muscular atrophy) this concept could be of high interest for targeting lncRNAs in kidney disease [88,89,90].